Navigation Links
New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
Date:9/18/2012

NEWTON, Mass., Sept. 18, 2012 /PRNewswire/ -- New England Cord Blood Bank, Inc. (NECBB) is pleased to announce that it now processes its cord blood using the Sepax 2 system from Biosafe.  Biosafe is the world leader in stem cell processing, serving stem cell banks, hospitals and research institutes alike with innovative cell processing solutions. 

Sepax 2 is a fully automated, mobile, closed capability system that provides the most efficient and consistent processing of umbilical cord blood. According to Brad Blaney, Laboratory Manager at NECBB, "From the day Sepax 2 was integrated into the lab, we saw a reduction in processing time and therefore an increase in our processing capacity.  The reliability, repeatability, and ease of use of the devices is great." The system involves processing of the umbilical cord blood via both its "plasma depletion" method and the "red cell reduction" method.  The Sepax system provides the NECBB client with exceptional post-thaw cell viability count.  This ensures that your family will have the greatest supply of high quality stem cells available should transplant become necessary.  Sepax processes every cord blood unit individually, respecting its biologic specificity and unique cell characteristics.

New England Cord Blood Bank, Inc. (NECBB) and its parent company, New England Cryogenic Center, Inc. have been pioneering forces in the cryogenic preservation of cells for over 30 years. At its International Headquarters, located just outside of Boston, Massachusetts, NECBB processes and stores lifesaving stem cells for thousands of families worldwide. Cord blood stem cells, obtained from the umbilical cord immediately following birth, are currently used to treat and cure more than 80 diseases. Successful transplants for cancer, anemia and other blood based diseases occur on a regular basis at approved transplant hospitals both domestically and internationally.

Most recently, families have begun to also bank the cord tissue itself. This tissue contains regenerative stem cells that have the potential to repair virtually any tissue in the human body. NECBB is proud to offer the processing of the cord tissue, at no additional cost, when families bank their child's cord blood at NECBB. 

New England Cord Blood Bank can be reached 24 hours per day at 1-888-700-2673 or visit their site at www.cordbloodbank.com.


'/>"/>
SOURCE New England Cord Blood Bank
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
5. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
6. FindTheBest Helps Parents Find Cord Blood Banks
7. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
10. Study finds chronic abnormal brain blood flow in Gulf War veterans
11. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... Friday, February 24, 2017 a total of 10,672,750 common share ... per common share. Proceeds from the exercise of these warrants ... Treasury.   ... "We are grateful for this expression of confidence by our ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
Breaking Biology News(10 mins):